Biophan Technologies, Inc., a developer of next-generation biomedical technology, has announced the online availability of a slide presentation by CEO Michael Weiner, outlining his views on the potential that nanotechnology will have on the future of biomedical devices and biomaterials. The presentation includes a review of Biophan's nanotechnology applications in a range of emerging multi-billion-dollar markets for biosciences and health care.
Mr. Weiner included the slide presentation in an address to a gathering of leading researchers and industry innovators attending the World Nano-Economic Congress on April 20-21, in Dublin, Ireland. Other presenters included representatives from Siemens, NEC, DSM, and Advance Nanotechnology. Biophan and its licensors currently hold 114 patents, licenses, and applications. Many of them are in areas of applied nanotechnology for the biomedical marketplace, representing one of the industry's most formidable intellectual property portfolios in several emerging markets.
The presentation outlines some of the Company's nano-based technologies, such as nanomagnetic particle coatings and resonant circuits that make stents and other hard-to-image devices imageable in Magnetic Resonance Imaging (MRI) systems. Applications of this technology in the $5 billion stent marketplace are designed to provide physicians with a range of advantages, including safer and more effective imaging options beyond X-ray and fluoroscopy, to clearly view inside implanted vascular stents to determine post-operative arterial health and device effectiveness. Biophan is developing other nanotechnology solutions including a battery powered by body heat, jointly being developed with NASA.
The presentation includes descriptions of research and development in Biophan's Nanolution division to create next-generation systems and products for the projected $40 billion drug-delivery marketplace. Several of Biophan's advanced drug-eluting coating technologies for stents and other implantable devices are outlined, including applications to allow on-demand surface elution for improved control over the drug-elution treatment, reloadable drug-eluting coatings that can be refreshed with new medicines for longer therapeutic courses, and guided drug delivery to target tumors or other specific sites.
Biophan invites all interested parties and investors to download and view the presentation by visiting http://www.tril02.com/biph/biph-wnec.ppt
